

DIAXONHIT – 2014 Consolidated Income

6% growth of *in vitro* diagnostic product sales at €27.9 M
2014 Consolidated Income: €30.6 M

Paris, France – January 26, 2015 - DIAXONHIT (Alternext : ALEHT, FR0004054427), a French leader in specialty *in vitro* diagnostics for transplantation, infectious diseases and cancer, announces today that its sales of *in vitro* diagnostic products increased by 6% and a consolidated income ⁽¹⁾ as of December 31, 2014 at €30.6 million, stable compared to consolidated income of €30.5 million as of December 31, 2013, despite the decrease in revenues derived from the collaboration with Allergan.

Total annual sales of *in vitro* diagnostic products recorded within Diaxonhit's commercial activities, reached €27.9 million, an increase of 6% compared to sales of €26.3 million recorded for the year 2013. This growth offset the decrease in revenues from R&D activities undertaken within the Allergan partnership.

« *Once again, our teams were successful in 2014 since the year was particularly difficult in France for the *in vitro* diagnostics industry with total yearly industry sales decreasing by 2.6% at the end of last November. Our focus on specialty diagnostics, and more specifically transplantation, infectious diseases and oncology, enabled our group to further progress this year with a 6% growth of *in vitro* diagnostics sales. Our group is now fully focused on specialty diagnostics with innovative R&D, integrated manufacturing and a dynamic commercial activity. We are ready for the commercialization of both BJI Inoplex and Allomap in 2015,* » commented Loïc Maurel, President of Diaxonhit's management board.

Next financial release: 2014 Full-year results, March 26, 2015

About DIAXONHIT

Diaxonhit (NYSE Alternext, FR0004054427, ALEHT) is a French fully integrated leader in *in vitro* diagnostics, involved from research to commercialization of specialty diagnostic products in the fields of transplantation, infectious diseases and cancer. With many partnerships and a strong presence in hospitals, Diaxonhit has an extensive commercialization network. Through its affiliate, InGen, it commercializes and services, mostly under exclusivity agreements, *in-vitro* diagnostic kits and advanced equipment, quality control products and rapid tests, including Tetanus Quick Stick[®], a proprietary product. InGen is the leading supplier in France of HLA tests manufactured by Thermo-Fisher/One Lambda, of which it is the largest commercial partner worldwide. The group also owns a diversified portfolio of products in development, including both innovative molecular and non-molecular diagnostics, covering its three main specialty areas: transplantation, immuno-infection and cancer. Diaxonhit headquarters are located in Paris and its affiliate in the Paris region. The Group is listed on NYSE Alternext in Paris and is part of both the NYSE Alternext OSEO Innovation and the Next Biotech indices. For more information, please visit: <http://www.diaxonhit.com>

Symbol : ALEHT - ISIN Code: FR0004054427 - Reuters : ALEHT.PA - Bloomberg : ALEHT:FP

¹ Income includes sales of *in vitro* diagnostic products and income related to R&D activities

Contacts

DIAXONHIT

Hervé Duchesne de Lamotte, CFO, +33 (0)1 53 94 52 49, herve.delamotte@diaxonhit.com

NewCap

Julien Perez, Investors Relations & Financial Communication, +33 (0)1 44 71 98 52, jperez@newcap.fr

Annie-Florence Loyer, Media Relations, +33 (0)1 44 71 98 50, afloyer@newcap.fr

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements about future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated. In addition, Diaxonhit, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only. Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.